Deanna L. Kirkpatrick

Davis Polk advised the underwriters, in connection with a $2.2 billion dual-listed U.S. and Canadian initial public offering of  75,000,000 subordinate voting shares ($1.425 billion)…

Davis Polk advised the sales agents in connection with certain amendments of the SEC-registered at-the-market offering program by Millendo Therapeutics, Inc. of up to $50 million gross…

Davis Polk advised VF Corporation in connection with an SEC-registered debt shelf takedown of €500 million aggregate principal amount of its 0.250% senior notes due 2028 (the “2028 notes”)…

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300,000 shares of its common stock. The common stock is listed on the…

Davis Polk advised the underwriters in connection with the offering of $2 billion aggregate principal amount of 1.375% U.S. dollar bonds due 2023 issued by Export Development Canada. Export…

Davis Polk advised the sole underwriter in connection with the initial public offering of 27,600,000 units of CITIC Capital Acquisition Corp., including 3,600,000 units purchased pursuant…

Davis Polk advised the joint book-running managers in connection with the $180 million initial public offering of common stock of Beam Therapeutics Inc. The common stock is listed on the…

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of $1 billion aggregate principal amount of its floating-rate senior notes due 2023, under its medium-term…

Davis Polk advised the underwriters in connection with the offering of $3 billion aggregate principal amount of 1.750% bonds due January 24, 2023 issued by the Province of Ontario. The…

Davis Polk advised the underwriters in connection with the offering of $3 billion aggregate principal amount of 1.625% U.S. dollar bonds due January 22, 2025, issued by Her Majesty in…